Researchers from Fundación Jiménez Díaz and affiliated organizations have published data from a study that aimed to identify new genes involved in the progression of atherosclerosis, a chronic multifactorial inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall.
Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent hereditary angioedema attacks, marking the first global approval for the drug that was discovered and developed in Australia by CSL scientists.
Inflammatory diseases specialist AB2 Bio Ltd. has signed a potential $686 million U.S. commercialization deal for its interleukin-18 neutralizing drug tadekinig. The agreement with Japanese pharma company Nippon Shinyaku Co. Ltd. includes an initial payment of $6 million, with a further $30 million due later this year.
Researchers from Sun Yat-Sen University and affiliated organizations presented data from a study that aimed to investigate mechanisms by which the CXC chemokine receptor 3 (CXCR3) antagonist, AMG-487, acts on autoimmune uveitis.
Researchers from Beijing Institute of Technology (BIT) and affiliated organizations presented the discovery and preclinical characterization of novel soluble epoxide hydrolase 2 (sEH) inhibitors as candidates for the treatment of inflammatory disorders.
Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, cancer, endocrine, inflammatory and neurological disorders.
Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
Kidney stones are largely composed of calcium oxalate (CaOx), which can cause serious renal inflammation and damage to renal tubular epithelial cells, with the CaOx crystals gradually accumulating and leading to CaOx nephrocalcinosis.
A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate receptor in mast cells.
Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 (STAT6) program that the Danish dermatology specialist has been working on since 2018.
RSS
